Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’

Investor retail chatter spiked for Jaguar Health Inc. on Wednesday after the company revealed its plan for a $1.5 million registered direct offering priced at-the-market under Nasdaq rules.

Jaguar Health shares fell 27.05% to close at $4.26 on Wednesday, before recovering 3.99% in after-hours trading to $4.43.

The biopharmaceutical company finalized agreements to exchange 246,306 shares of common stock for $6.09 per share. 

Jaguar will distribute unregistered warrants in a simultaneous private placement. The exercise price is $5.84 per share, and purchasers can buy up to 492,612 shares. 

These warrants become exercisable immediately and expire after a fundamental transaction or liquidation event occurs or after 24 months, whichever condition is first met.

The offering's closure is scheduled for May 22, subject to standard conditions. H.C. Wainwright & Co. holds exclusive placement agency responsibilities.

Jaguar plans to use net proceeds to finance general corporate purposes, such as growth capital funding, working capital maintenance, convertible note repayment, and capital expenditure needs.

On Stocktwits, retail sentiment was ‘bullish’ amid a 444% surge in 24-hour message volume.

Some retail traders described the offering as a “dip opportunity,” pointing to prior disclosures about share sales through the at-the-market program and suggesting the move had been anticipated since 2022. 

Others framed the discounted pricing as a potential entry point, expressing optimism about upcoming news and the company’s trajectory.

The stock has declined 84.4% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.